A systematic review and meta-analysis of the efficacy and adverse events of azacitidine-plus-lenalidomide treatment for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia¹

1 Supplemental data for this article can be accessed https://doi.org/10.1080/16078454.2019.1631425.

ABSTRACT

Objectives:

The addition of lenalidomide (LEN) to azacitidine (AZA) may further improve the outcomes of acute myeloid leukemia (AML) patients as well as patients with high-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) patients although the evidence for this combination treatment is still relatively limited. This meta-analysis aimed to evaluate efficacy and adverse effects of AZA plus LEN for the treatment of patients with high-risk MDS, AML or CMML.

Methods:

The current study systematically identified all cohort studies of patients with AML and/or MDS and/or CMML who received AZA in combination with LEN that reported the overall complete remission (CR) rate and/or overall response rate (ORR). A DerSimonian–d random–effects model with double arcsine transformation was used for the pooled rates and 95% confidence interval (CI) of the all outcomes.

Results:

A total of 10 studies with 406 patients were identified and included into the meta-analysis. The pooled CR rate after the treatment with AZA-plus-LEN regimen was 33.0% (95% CI, 27.7%–38.7%, I² = 18%) while the pooled ORR was 49.9% (95% CI, 38.4%–61.5%, I² = 72%). Nonetheless, adverse events including grade 3–4 neutrophil toxicity events, platelet toxicity events and febrile neutropenia were common with AZA-plus-LEN regimen.

Conclusions:

The current study may serve as a preliminary data to suggest that the addition of LEN may offer incremental benefit to patients with high-risk MDS, AML and CMML. However, randomized-controlled studies that directly compare the efficacy and adverse events of AZA-plus-LEN regimen versus AZA monotherapy are still needed.

KEYWORDS:

• :Azacitidine
• lenalidomide
• acute myeloid leukemia
• myelodysplastic syndrome
• chronic myelomonocytic leukemia

Disclosure statement

No potential conflict of interest was reported by the authors.

Ethics approval and consent to participate

The need for ethics approval by an institutional board review was waived as this study does not directly involve human subjects.

Availability of data and material

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

ORCID

Patompong Ungprasert http://orcid.org/0000-0002-4817-9404

Weerapat Owattanapanich http://orcid.org/0000-0002-1262-2005

Notes

1 Supplemental data for this article can be accessed https://doi.org/10.1080/16078454.2019.1631425.